El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

719287.pdf (2.27 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2021-03-31

Llicència de publicació

cc-by-nc-nd (c) Elsevier B.V., 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183693

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.rmed.2020.106220

Resum

Objective: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results: In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). Conclusion: Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.

Matèries

Hipertensió pulmonar

Matèries (anglès)

Pulmonary hypertension

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

GHOFRANI, Hossein-ardeschir, GÓMEZ SÁNCHEZ, Miguel a., HUMBERT, Marc, PITTROW, David, SIMONNEAU, Gérald, GALL, Henning, GRÜNIG, Ekkehard, KLOSE, Hans, HALANK, Michael, LANGLEBEN, David, SNIJDER, Repke j., ESCRIBANO SUBIAS, Pilar, MIELNICZUK, Lisa m., LANGE, Tobias j., VACHIÉRY, Jean-luc, WIRTZ, Hubert, HELMERSEN, Douglas s., TSANGARIS, Iraklis, BARBERÀ I MIR, Joan albert, PEPKE-ZABA, Joanna, BOONSTRA, Anco, ROSENKRANZ, Stephan, ULRICH, Silvia, STERINGER-MASCHERBAUER, Regina, DELCROIX, Marion, JANSA, Pavel, IMKOVÁ, Iveta, GIANNAKOULAS, George, KLOTSCHE, Jens, WILLIAMS, Evgenia, MEIER, Christian, HOEPER, Marius m. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. _Respiratory Medicine_. 2021. Vol. 178, núm. 106220. [consulta: 31 de desembre de 2025]. ISSN: 0954-6111. [Disponible a: https://hdl.handle.net/2445/183693]

Exportar metadades

JSON - METS

Compartir registre